|
|
Blood, 1 October 2004, Vol. 104, No. 7, pp. 1979-1988.
Prepublished online as a Blood First Edition Paper on June 15, 2004; DOI 10.1182/blood-2004-02-0711.
 Previous Article | Next Article 
Submitted March 12, 2004
Accepted May 20, 2004
Long-Term Survival Benefit and Improved Complete Cytogenetic and Molecular Response Rates with Imatinib Mesylate in Philadelphia Chromosome-Positive, Chronic-Phase Chronic Myeloid Leukemia after Failure of Interferon-
Hagop M Kantarjian*, Jorge E Cortes, Susan O'Brien, Rajyalakshmi Luthra, Francis Giles, Srdan Verstovsek, Stefan Faderl, Deborah Thomas, Guillermo Garcia-Manero, Mary Beth Rios, Jianqin Shan, Dan Jones, and Moshe Talpaz
Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Bioimmunotherapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
* Corresponding author; email: hkantarj{at}mdanderson.org.
We reviewed 261 patients with chronic phase chronic myelogenous leukemia (CML) post interferon- (IFN) failure treated with imatinib 400 mg daily. With a median follow-up time of 45 months, the major cytogenetic response rate was 73%, and the complete cytogenetic response rate 63%. The estimated 4-year survival rate was 86%. Multivariate analysis for survival identified hematologic resistance to IFN (p = 0.01), splenomegaly (p = 0.03), and lack of any cytogenetic response after 3 months of therapy (p = 0.01) to have independent poor prognostic significance. Patients could be divided into good (no adverse factors), intermediate (1 adverse factor), and poor risk groups (2 or 3 adverse factors; 12% of patients) with estimated 4-year survival rates of 96%, 86% and 49%, respectively (p < 0.00001). The 4-year cumulative major molecular response (QPCR= BCR-ABL/ABL <0.05%) rate was 43%, and complete molecular response rate (BCR-ABL undetectable) 26%. Compared with a historical group of 251 similar patients treated with non-imatinib therapies, imatinib was associated with a better 4-year survival rate (86%, versus 43% p<0.0001); the survival advantage was confirmed by multivariate analysis (hazard ratio 0.19, p<0.0001).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. H. Kim, L. Sriharsha, W. Xu, S. Kamel-Reid, X. Liu, K. Siminovitch, H. A. Messner, and J. H. Lipton
Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia
Clin. Cancer Res.,
July 15, 2009;
15(14):
4750 - 4758.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Palandri, I. Iacobucci, S. Soverini, F. Castagnetti, A. Poerio, N. Testoni, G. Alimena, M. Breccia, G. Rege-Cambrin, M. Tiribelli, et al.
Treatment of Philadelphia-Positive Chronic Myeloid Leukemia with Imatinib: Importance of a Stable Molecular Response
Clin. Cancer Res.,
February 1, 2009;
15(3):
1059 - 1063.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. M. Yong, K. Keyvanfar, N. Hensel, R. Eniafe, B. N. Savani, M. Berg, A. Lundqvist, S. Adams, E. M. Sloand, J. M. Goldman, et al.
Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib
Blood,
January 22, 2009;
113(4):
875 - 882.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. P. Hughes, S. Branford, D. L. White, J. Reynolds, R. Koelmeyer, J. F. Seymour, K. Taylor, C. Arthur, A. Schwarer, J. Morton, et al.
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
Blood,
November 15, 2008;
112(10):
3965 - 3973.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Khorashad, H. de Lavallade, J. F. Apperley, D. Milojkovic, A. G. Reid, M. Bua, R. Szydlo, E. Olavarria, J. Kaeda, J. M. Goldman, et al.
Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression
J. Clin. Oncol.,
October 10, 2008;
26(29):
4806 - 4813.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Zhang, P. J. Kaplan-Lefko, K. Rex, Y. Yang, J. Moriguchi, T. Osgood, B. Mattson, A. Coxon, M. Reese, T.-S. Kim, et al.
Identification of a Novel Recepteur d'Origine Nantais/c-Met Small-Molecule Kinase Inhibitor with Antitumor Activity In vivo
Cancer Res.,
August 15, 2008;
68(16):
6680 - 6687.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Palandri, I. Iacobucci, F. Castagnetti, N. Testoni, A. Poerio, M. Amabile, M. Breccia, T. Intermesoli, F. Iuliano, G. Rege-Cambrin, et al.
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-{alpha}: 5-year outcome
Haematologica,
May 1, 2008;
93(5):
770 - 774.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Hochhaus, B. Druker, C. Sawyers, F. Guilhot, C. A. Schiffer, J. Cortes, D. W. Niederwieser, C. Gambacorti-Passerini, R. M. Stone, J. Goldman, et al.
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-{alpha} treatment
Blood,
February 1, 2008;
111(3):
1039 - 1043.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Palandri, I. Iacobucci, G. Martinelli, M. Amabile, A. Poerio, N. Testoni, S. Soverini, F. Castagnetti, A. De Vivo, M. Breccia, et al.
Long-Term Outcome of Complete Cytogenetic Responders After Imatinib 400 mg in Late Chronic Phase, Philadelphia-Positive Chronic Myeloid Leukemia: The GIMEMA Working Party on CML
J. Clin. Oncol.,
January 1, 2008;
26(1):
106 - 111.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Branford, J. F. Seymour, A. Grigg, C. Arthur, Z. Rudzki, K. Lynch, and T. Hughes
BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria
Clin. Cancer Res.,
December 1, 2007;
13(23):
7080 - 7085.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Palandri, I. Iacobucci, F. Quarantelli, F. Castagnetti, D. Cilloni, M. Baccarani, and on behalf of the GIMEMA Working Party on CML
Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase
Haematologica,
November 1, 2007;
92(11):
1579 - 1580.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Press, C. Galderisi, R. Yang, C. Rempfer, S. G. Willis, M. J. Mauro, B. J. Druker, and M. W.N. Deininger
A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response
Clin. Cancer Res.,
October 15, 2007;
13(20):
6136 - 6143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Jabbour, H. M. Kantarjian, L. V. Abruzzo, S. O'Brien, G. Garcia-Manero, S. Verstovsek, J. Shan, M. B. Rios, and J. Cortes
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Blood,
October 15, 2007;
110(8):
2991 - 2995.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. M. Yong, K. Rezvani, B. N. Savani, R. Eniafe, S. Mielke, J. M. Goldman, and A. J. Barrett
High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects
Blood,
July 15, 2007;
110(2):
770 - 775.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Volpe, A. Cignetti, C. Panuzzo, M. Kuka, K. Vitaggio, M. Brancaccio, G. Perrone, M. Rinaldi, G. Prato, M. Fava, et al.
Alternative BCR/ABL Splice Variants in Philadelphia Chromosome-Positive Leukemias Result in Novel Tumor-Specific Fusion Proteins that May Represent Potential Targets for Immunotherapy Approaches
Cancer Res.,
June 1, 2007;
67(11):
5300 - 5307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Jobbagy, R. van Atta, K. M. Murphy, J. R. Eshleman, and C. D. Gocke
Evaluation of the Cepheid GeneXpert BCR-ABL Assay
J. Mol. Diagn.,
April 1, 2007;
9(2):
220 - 227.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Ma, R. Tseng, M. Gorre, I. Jilani, M. Keating, H. Kantarjian, J. Cortes, S. O'Brien, F. Giles, and M. Albitar
Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia
Haematologica,
February 1, 2007;
92(2):
170 - 175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Quintas-Cardama, H. Kantarjian, D. Jones, C. Nicaise, S. O'Brien, F. Giles, M. Talpaz, and J. Cortes
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure
Blood,
January 15, 2007;
109(2):
497 - 499.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. R. Luo, Z. Yang, A. Camuso, R. Smykla, K. McGlinchey, K. Fager, C. Flefleh, S. Castaneda, I. Inigo, D. Kan, et al.
Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure
Clin. Cancer Res.,
December 1, 2006;
12(23):
7180 - 7186.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, et al.
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Blood,
September 15, 2006;
108(6):
1809 - 1820.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi, G. Barosi, R. A. Mesa, F. Cervantes, H. J. Deeg, J. T. Reilly, S. Verstovsek, B. Dupriez, R. T. Silver, O. Odenike, et al.
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
Blood,
September 1, 2006;
108(5):
1497 - 1503.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Quintas-Cardama and J. E. Cortes
Chronic Myeloid Leukemia: Diagnosis and Treatment
Mayo Clin. Proc.,
July 1, 2006;
81(7):
973 - 988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Press, Z. Love, A. A. Tronnes, R. Yang, T. Tran, S. Mongoue-Tchokote, M. Mori, M. J. Mauro, M. W. Deininger, and B. J. Druker
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML
Blood,
June 1, 2006;
107(11):
4250 - 4256.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Golemovic, S. Verstovsek, F. Giles, J. Cortes, T. Manshouri, P. W. Manley, J. Mestan, M. Dugan, L. Alland, J. D. Griffin, et al.
AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia
Clin. Cancer Res.,
July 1, 2005;
11(13):
4941 - 4947.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Chen and W. Plunkett
Sequential Blockade of Oncogenic Kinases
Am. Assoc. Cancer Res. Educ. Book,
April 1, 2005;
2005(1):
344 - 348.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi, G. W. Dewald, M. L. Litzow, J. Cortes, M. J. Mauro, M. Talpaz, and H. M. Kantarjian
Chronic Myeloid Leukemia: Current Application of Cytogenetics and Molecular Testing for Diagnosis and Treatment
Mayo Clin. Proc.,
March 1, 2005;
80(3):
390 - 402.
[Abstract]
[PDF]
|
|
|
|
|
